- IMVT +1.90%
Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now. Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on Immunovant, Inc. (NASDAQ:IMVT) on November 11 with a price target of $54. The company’s reported earnings per share of -$0.73 fell short of the -$0.71 consensus estimate. With $4.4 billion in cash and no debt on its balance sheet, Immunovant, Inc. (NASDAQ:IMVT) maintains a strong capital position in despite these deficits.
Source: Pixabay
The company intends to publish results from a proof-of-concept study in cutaneous lupus and preliminary clinical data for IMVT-1402 in ACPA+ difficult-to-treat rheumatoid arthritis in 2026. According to Oppenheimer, the medication is “positioned as best-in-class” and has “considerable upside” as it moves closer to possible commercialization across multiple indications.
Immunovant, Inc. (NASDAQ:IMVT) is also testing a second drug candidate, batoclimab, in mid-late-stage trials for two separate autoimmune conditions: GD and thyroid eye disease (TED).
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage immunology company focused on developing innovative therapies for autoimmune diseases. The company’s primary focus is on creating anti-FcRn (neonatal Fc receptor) antibodies which aim to reduce harmful immunoglobulin G (IgG) autoantibodies in patients with various autoimmune conditions.
While we acknowledge the potential of IMVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy Privacy Dashboard More Info
